SFDA To Review Qualifications Of Clinical Drug Trial Organizations
This article was originally published in PharmAsia News
Executive Summary
China's State FDA recently circulated a notice asking all healthcare institutions with clinical drug trial qualifications to apply for local provincial health administration qualification confirmation if they want to continue conducting clinical trials after certification expires. The circular requests clinical trial organizations that received SFDA approval before Jan. 1, 2007 to submit their review applications by June 10 for consideration by SFDA and the Ministry of Health in 2009. Organizations that received approval after that date should reapply six months before the expiry date. Companies that do not submit applications for review within the stipulated time frame will lose their clinical trial qualifications. During the review period, new applications for joining the clinical trial sector will not be accepted. (Click here for more - Chinese Language)
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.